Journal of Nuclear medicine Jul 2023, 64 (7) 1024-1029; DOI: 10.2967/jnumed.122.265242
In the Featured Article of the Month from JNM an International Multicenter group propose a PSMA PET tumor–to–salivary gland ratio (PSG score) to predict outcomes after [177Lu]PSMA. The PSG score was prognostic for PSA progression-free survival and overall survival after [177Lu]PSMA. The visual PSG score assessed on 3-dimensional maximum-intensity-projection PET images yielded substantial reproducibility and comparable prognostic value to the quantitative score.
Of the 237 patients, the numbers in the high, intermediate, and low groups were 56 (23.6%), 163 (68.8%), and 18 (7.6%), respectively, for qPSG score and 106 (44.7%), 96 (40.5%), and 35 (14.8%), respectively, for vPSG score. The more than 50% prostate-specific antigen decline was better in patients with a higher PSG score. The median PSA progression-free survival of the high, intermediate, and low groups by qPSG score was 7.2, 4.0, and 1.9 mo (P < 0.001). The median OS of the high, intermediate, and low groups was 15.0, 11.2, and 13.9 mo (P = 0.017).